A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Mineki Takechi

Cardio Intelligence Inc. Chief Development Officer
Director

After working at Fujitsu Ltd. on the development of products and services such as image processing system and cloud information service for home healthcare, as well as research and development in information retrieval and AI, and new business development, I engaged in the construction of a pulmonary hypertension patient registry at the International University of Health and Welfare Mita Hospital. Since 2020, I have been serving as CDO at Cardio Intelligence Inc., responsible for the development of software medical devices for arrhythmia analysis and regulatory affairs. Since 2021, I have also been serving as COO, overseeing overall business planning and execution.

Tomoko Maeda-Chubachi

TMC Clinical Development Consulting, Inc, President; The Institute of Drug Development Career Promotion, Founding Director; Japan Alliance of Medical School Startups, Director

Dr. Maeda-Chubachi is an advisor and consultant for pharmaceutical and biotech companies and was the Chief Medical Officer at Pelthos Therapeutics (previously Novan), leading First-in-Human to launch preparation. Tomoko is known for her expertise in drug development with over 20 years industry experience. She has led clinical and medical affairs in large pharma as well as a small biotech. She led global drug development teams, resulting in 8 approvals in multiple regions, including Xalatan, Xeljanz, Taltz, Vtama, and Zelsuvmi.　Tomoko has broad knowledge of drug development, of which process is highly regulated and need thorough risk assessment, management, and control. As a Chief Medical Officer, she worked closely with the CEO and board about the strategy and governance.

Yutaka Tomioka

Project Researcher, Department for the Promotion of Medical Device Innovation, National Cancer Center Hospital East.
Chief Regulatory Scientist, ayumo Inc.
Chief Development Officer / Director, Atransen Technologies, Inc.

Ph.D. (Engineering). I began my career at the Pharmaceuticals and Medical Devices Agency (PMDA), where I worked in medical device review and reliability inspection (reliability standards compliance inspections and on-site GCP inspections for medical devices). My responsibilities included the approval review, consultation services, and reliability inspections for a wide range of medical devices, including novel medical devices. Drawing on my 10 years of experience at the regulatory authority, I moved to National Cancer Center Hospital East in July 2019 to support the development of medical devices originating in Japan. At National Cancer Center Hospital East, I supported medical device development led by both academic institutions and companies. I left my full-time position at National Cancer Center Hospital East at the end of 2025, and joined ayumo Inc. in January 2026 (current position), where I lead the regulatory affairs team.I also joined Atransen Technologies, Inc. in May 2026 (current position). I currently hold part-time positions at National Cancer Center Hospital East, Yokohama City University, and the National Defense Medical College, while also supporting a number of startups, pharmaceutical companies, medical device manufacturers, academic institutions, and small manufacturing workshops (machi-koba) in Ota Ward, Tokyo.

Tadashi Sameshima

I have been engaged in product development and business operations of medical devices and regenerative medicine products for 37 years at Terumo Corporation. I have experienced the development of medical devices such as extracorporeal circulatory and blood transfusion devices, as well as the development to commercialization of cellular products. In addition, I am able to provide specific advice on various stages of development based on my participation in joint research with universities, collaboration among companies, discussions with government agencies, and activities of industry associations.

Kazufumi Nakamura

Mitsui & Co. Global Investment, Inc.　Investment Director

Kazufumi Nakamura is an Investment Director focused on the investment in biotech in US and China. By leveraging his experiences and networks in Pharma, Biotech and Academia, he connects companies to those experts to expand business and gain scientific insight to help the companies succeed with their important missions.
Kazufumi has over 20 years of healthcare and life sciences experience, spanning business development, investment, entrepreneurship and R&D. Prior to joining MGI, he co-founded a biotech to accelerate innovations through academic institutions in Japan. Previously, he engaged in business development and conducted scientific evaluation, and license-in and license-out of pharmaceutical products at Santen Pharmaceuticals. In addition, he was responsible for creating relationships with the leading academic institutions and innovators, gaining Santen early access to innovation. Prior to Santen, he held a number of clinical development roles at Janssen Pharmaceuticals, including the development of Alzheimer’s disease and Rheumatoid arthritis programs.